Non-interaction of spironolactone medication and cortisol metabolism in man.
In 5 healthy subjects and in 5 patients with decompensated liver diseases, the concentrations of cortisol, canrenone and canrenoate-K were determined after single doses and after a long-term treatment with spironolactone. The concentrations of the metabolites of spironolactone were determined fluorimetrically, those of cortisol by a highly specific radioimmunoassay with previous chromatographic separation. As a result, non-interaction between spironolactone medication and cortisol metabolism, even at high dose and long-term treatment conditions, was established neither in normal test subjects nor in patients with liver failure.
D002191:Canrenoic Acid / Q000097:blood; D002192:Canrenone / Q000097:blood; D004347:Drug Interactions; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000378:metabolism*; D008107:Liver Diseases / Q000097:blood / Q000188:drug therapy; D013148:Spironolactone / Q000378:metabolism / Q000627:therapeutic use*
D013148:Spironolactone; D002192:Canrenone; D002191:Canrenoic Acid; D006854:Hydrocortisone